Results 211 to 220 of about 177,862 (267)

Motor and Cognitive Outcome After Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease Harboring GBA1 Variant

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Deep brain stimulation (DBS) is effective for Parkinson's disease (PD); however, its efficacy varies with genetic background, such as the GBA1 variant—the causative gene of Gaucher disease—associated with increased PD risk and cognitive decline after subthalamic nucleus (STN)‐DBS.
Hikaru Kamo, Genko Oyama, Mai Shimizu, Haruka Takeshige‐Amano, Takashi Ogawa, Wataru Sako, Noriko Nishikawa, Taku Hatano, Yuanzhe Li, Hiroyo Yoshino, Manabu Funayama, Masanobu Ito, Hirokazu Iwamuro, Atsushi Umemura, Nobutaka Hattori   +14 more
wiley   +1 more source

L. johnsonii alleviates methamphetamine craving via the metabolism of tyrosine. [PDF]

Microbiome
Zhang R, Cheng Z, Liu D, Shao Q, Sheng W, Xu H, Xu P, Wang Y, Aa J, Wang G, Xie Y.   +10 more
europepmc   +1 more source

Astrocyte FGF7/FGFR2 autocrine signaling mediates neuroinflammation and promotes MPTP-induced degeneration of dopaminergic neurons

Xin Sun, Yueping Wang, Yajie Zhang, Ruixue Han, Min Wang, Jing Zhang, Ting Sun, Yang Liu, Gang Hu, Lei Cao, Ming Lu   +10 more
openalex   +1 more source

Basal Forebrain Volume and Concurrent Hallucinations and Mild Cognitive Impairment in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Visual hallucinations (VH) and mild cognitive impairment (MCI) often co‐occur in Parkinson's Disease (PD). Each symptom in isolation is associated with cholinergic basal forebrain (BF) atrophy. However, it is unclear whether BF integrity relates to one symptom preferentially or to their co‐occurrence, and whether this relationship ...
Sabrina M. Adamo, Vaishali Mutreja, Marta Statucka, Batu Kaya, Taylor W. Schmitz, Anthony C. Ruocco, Melanie Cohn   +6 more
wiley   +1 more source

Bridging the gap in Parkinson's disease research: from general pathophysiology to advanced 3d cell culture models. [PDF]

Cell Commun Signal
Keles B, Rumman B, Samarie MAJA, Gürsoy Özdemir Y, Öztop Cakmak Ö, Akyoldas G, Ertan S, Sokullu E.   +7 more
europepmc   +1 more source

Bromocriptine, Selegiline and Amantadine in the Treatment of Depression-A Systematic Review. [PDF]

Pharmaceuticals (Basel)
Bieś R, Krzystanek M, Górski M, Koźmin-Burzyńska A, Warchala A, Trędzbor B, Martyniak E, Fojcik J.   +7 more
europepmc   +1 more source

Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties

Movement Disorders Clinical Practice, EarlyView.
Abstract Background α‐synuclein seeding amplification assay (α‐synuclein SAA) development as a diagnostic biomarker for Parkinson's disease (PD) has shown promising results over the past decade. However, the utility of these assays in the prediction of disease progression is unclear.
Daniel Belete, Christian Mattjie, Brook Huxford, Jonathan P. Bestwick, Alastair J. Noyce, Cristina Simonet   +5 more
wiley   +1 more source

Quantitative susceptibility mapping of deep brain nuclei in 22q11.2 deletion syndrome. [PDF]

Front Psychiatry
Muñoz N, García M, Cuiza A, Tepper A, Vásquez J, Ramirez-Mahaluf JP, Barbagelata D, Aguirre J, Maldonado ME, Ornstein C, Fritsch R, Repetto G, Milovic C, Andia ME, Crossley NA, Tejos C.   +15 more
europepmc   +1 more source